Loomis Sayles & Co. L P Buys 192,080 Shares of Xencor, Inc. (NASDAQ:XNCR)

Loomis Sayles & Co. L P lifted its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 21.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,092,346 shares of the biopharmaceutical company's stock after acquiring an additional 192,080 shares during the period. Loomis Sayles & Co. L P owned about 1.56% of Xencor worth $25,102,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of XNCR. Sanctuary Advisors LLC bought a new stake in Xencor in the 3rd quarter valued at about $540,000. Barclays PLC grew its holdings in Xencor by 100.7% in the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock worth $3,128,000 after buying an additional 78,066 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Xencor in the 3rd quarter valued at approximately $362,000. Jane Street Group LLC increased its position in Xencor by 18.6% in the 3rd quarter. Jane Street Group LLC now owns 168,431 shares of the biopharmaceutical company's stock valued at $3,387,000 after acquiring an additional 26,473 shares during the period. Finally, Geode Capital Management LLC raised its stake in Xencor by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company's stock valued at $29,273,000 after acquiring an additional 17,658 shares in the last quarter.

Xencor Stock Performance

XNCR stock traded down $0.15 during midday trading on Tuesday, hitting $10.49. The stock had a trading volume of 191,469 shares, compared to its average volume of 594,961. Xencor, Inc. has a 52 week low of $10.17 and a 52 week high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $15.39 and a 200 day simple moving average of $20.01. The firm has a market capitalization of $739.15 million, a price-to-earnings ratio of -3.27 and a beta of 0.74.

Remove Ads

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.19. The firm had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. As a group, equities research analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on XNCR. StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company decreased their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Finally, Piper Sandler raised Xencor from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Xencor has a consensus rating of "Moderate Buy" and a consensus price target of $34.38.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.